Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
A medication that reduces alcohol consumption as a side effect of treatment for other conditions like obesity could reach this population in ways that traditional addiction treatments cannot
A data-independent (DIA) acquisition method was used, in which one full scan (3001,650 m/z , maximum ion fill time of 45 ms, normalized AGC target 300%, R = 120.000 at 200 m/z ) was followed by 66 tMS2 fragment scans of unequally spaced windows with 1 Th overlap, covering the same m/z range (fill time 22 ms, normalized AGC target 1,000%, normalized high-collision density energy of 30%, R = 15.000)
In December 2025, Eli Lilly announced positive topline results from TRIUMPH-4 a 68-week Phase 3 trial in adults with obesity and knee osteoarthritis in which retatrutide delivered average weight loss of up to 71.2 lbs alongside substantial reductions in osteoarthritis pain
Experimental investigations have reported changes in antioxidant enzyme activity and oxidative markers following Epithalon exposure in controlled environments
